BRUIN CLL-321: A phase 3 open-label, randomized study of pirtobrutinib versus investigator's choice of idelalisib plus rituximab or bendamustine plus rituximab in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma.
| Autor: | Follows, George, Burke, John M., Grosicki, Sebastian, Chen, Christine, Sanna, Alessandro, Roeker, Lindsey Elizabeth, Yi, Shuhua, Munir, Talha, de la Cruz, Fátima, Ferrant, Emmanuelle, Mátrai, Zoltán, Ghia, Paolo, Jurczak, Wojciech, Bosch, Francesc, Hill, Marisa E., Wang, Denise, Guntur, Ananya, Leow, Ching Ching, Sharman, Jeff Porter, Barr, Paul M. |
|---|---|
| Zdroj: | Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, pTPS7582-TPS7582, 1p |
| Databáze: | Supplemental Index |
| Externí odkaz: |
|